TRPC Knockout (KO) Mice and Mice with a Floxed Allele of TRPC Ion Channel Genes
Novel Human Rotavirus Vaccine CDC-6 Strain for Impacted Subgroup, the Lewis Negative Population
A Novel Rapid Point-of Care Diagnostic Method for Infectious and Autoimmune Diseases
Potential New Drugs for Treating or Preventing Pruritus
Thyclotide Peptide Conjugates With Cell Permeability And Inhibitory Activity
Thyclotides are oligomeric molecules with chiral tetrahydrofuran (THF) diamine units consisting of either R,R or
S,S stereochemistry. Thyclotide sequences with R,R stereochemistry bind to complementary DNA and RNA
sequences with strong affinity and sequence specificity, while thyclotides with S,S stereochemistry have a helical
handedness that does not allow binding to DNA or RNA. Thyclotides are cell permeable and can be used to
suppress microRNA activity in cells. Peptides are oligomeric molecules consisting of amino acids found in
Sidechain Functionalized S-Acylbenzamides With Anti-HIV Activity
HIV infection remains a major medical problem, with approximately 38 million people worldwide living with HIV. Nipamovir and SAMT-247 are simple and inexpensive small molecules that inactivate HIV virus by interference with final maturation steps of the virus. This mechanism provides a high barrier for HIV to develop resistance. In fact, lab experiments designed to encourage HIV to develop resistance to Nipamovir and SAMT-247 have all failed. In animal tests, Nipamovir and SAMT-247 do not display toxic side effects.
Novel HPPK (Bacterial Protein) Inhibitors for Use as Antibacterial Agents
Research and development leading to the discovery of novel antibiotics has waned in recent years. At the same time, the emergence and spread of antimicrobial resistance has compounded the global danger to human health from bacterial infections.
A Method to Isolate Tumor Specific T-Cells or T-Cell Receptors from Peripheral Blood using In-vitro Stimulation of Memory T-Cells
Adoptive cell transfer (ACT) and T-cell receptor (TCR) therapies use lymphocytes that target somatic mutations expressed by tumors cells to treat cancer patients. One of the challenges of these therapies is the identification and isolation of mutation-specific cells and TCRs. While neoantigen specific cells are relatively abundant in the tumor, they are far less common in peripheral blood, a more accessible source of T cells.
Chimeric Antigen Receptor (CAR) that Targets Chemokine Receptor CCR4 and its Use in Treating Cancer
The chemokine receptor, CCR4 is a seven transmembrane G protein-coupled cell surface receptor molecule with selective expression on cells of the hematopoietic system. In adult T cell leukemia (ATL), the cell-surface expression of CCR4 on leukemic cells has been found to be nearly universal. Therefore, a CCR4-directed chimeric antigen receptor (CAR) -cell may provide an effective therapeutic against ATL.